A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Post-Conference Report Provides HIV Cure Roadmap
Life Expectancy With HIV Increases Dramatically
Improper Use of a Neti Pot Can Be Fatal
Animal Studies Suggest Anti-Reservoir Drugs May Help 'Functionally Cure' HIV
Tenofovir Microbicide Gel Falters in Major HIV Prevention Study
Gold Drug Shows HIV Eradication Potential
New Studies Under Way of Sangamo's Possible 'Functional Cure' Gene Therapy
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

October 29, 2008

EMD Serono Buys Rights to Sell Tesamorelin in U.S.

Theratechnologies announced today that it has sold the rights to sell the experimental lipodystrophy drug tesamorelin in the United States—if the drug is approved by the U.S. Food and Drug Administration—to EMD Serono. Tesamorlin prompts the body to produce more growth hormone and has been shown to reduce some of the fat accumulation seen in people with HIV-related lipodystrophy.

Serono also makes Serostim, a manufactured form of human growth hormone approved to treat HIV-related wasting syndrome. Serostim has been studied for treating fat accumulation in people living with HIV, but Serono has been unable to secure approval for this indication due to side effect concerns and limited long-term safety and effectiveness results.

Tesamorelin is currently being evaluated in a second yearlong Phase III study and has been shown to be just as effective with less toxicity—including effects on sugar (glucose) levels in the blood—than Serostim.  

Theratechnologies will receive an up-front payment of $30 million dollars and will ultimately be paid $215 million or more over time.

Search: Theratechnologies, Serono, Tesamorelin, Serostim, human growth hormone, releasing factor, lipodystrophy, license agreement


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

steven, , 2008-11-05 12:57:31
My understanding is that the second yearlong phase III study of tesamorelin has been completed (I was in the first). I've sent repeated emails and letters to Theratechnologies with no reponse . . . you'd think that I'm at least minimally responsible for the 23 mil. going intro their pockets. clinicaltrial.gov doesn't show any recruitment.

Jerry Robbins, Saint Petersburg, 2008-11-05 10:04:51
THIS is great, Real great progress

comments 1 - 2 (of 2 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dambitious
    Baltimore Co.
    Maryland


    sevane
    Los Angeles
    California


    4everdreamer
    fort lauderdale
    Florida


    Xufwat
    Miami
    Florida
Click here to join POZ Personals!
Conference Coverage

6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


XVIII International AIDS Conference
Vienna, Austria
July 18-23, 2010

more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.